The ranking of the APC-binding molecules tested in the second experiment based on improved tumor control, and induction of reactive CD8+ and CD4+ T cells, pointed to CCL19_Neo5 as the most efficient APC-targeting construct (Supplementary Table 3 bottom). The gene discussed is CD8A; the disease is neoplasm.